{
  "id": 14482260,
  "title": "Verastem makes its stand as a RevMed competitor in pancreatic cancer",
  "url": "https://urgent.news/2026/10/14/verastem-makes-its-stand-as-a-revmed-competitor-in-pancreatic-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-14T15:52:24.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/verastem-makes-its-stand-as-a-revmed-competitor-in-pancreatic-cancer/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Verastem Oncology had a big Wednesday morning: it announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massachusetts ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}